After enduring the chill of a prolonged capital winter, China's drugmakers have begun to feel a thawing breeze.
Caixin
Chinese pharma turns to global deals to cure capital crunch
Sales of drug rights and M&A transactions help offset investment slump
In 2023, the number of China’s outbound deals involving rights for treatments exceeded the number of inbound deals for the first time.
Read Next
Latest on Caixin
